MAPT and tauopathy: It is possible that varlitinib regulates other neuroinflammation-related molecular targets (e.g., DYRK1A, which is reduced in varlitinib-treated tau-overexpressing PS19 mice and is an important molecule for neuroinflammation) to alter tauopathy-induced neuroinflammation, which will be investigated in future studies.